Anthracycline News and Research

RSS
Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.
INS cites FDA-approved Totect antidote for anthracycline extravasations

INS cites FDA-approved Totect antidote for anthracycline extravasations

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Combination therapy improves overall survival in women with advanced breast cancer

Combination therapy improves overall survival in women with advanced breast cancer

Genentech announces positive results from Phase II study of T-DM1

Genentech announces positive results from Phase II study of T-DM1

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

Chemotherapy improves overall survival in postmenopausal breast cancer patients

Chemotherapy improves overall survival in postmenopausal breast cancer patients

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced

Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced

Updated results from phase III EXTEND clinical trial of pixantrone released

Updated results from phase III EXTEND clinical trial of pixantrone released

New treatment options for leukemia and myeloproliferative disorders introduced

New treatment options for leukemia and myeloproliferative disorders introduced

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Genentech submits sBLAs to the FDA for Avastin

Genentech submits sBLAs to the FDA for Avastin

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

Eisai reports global Phase III study results of eribulin mesylate

Eisai reports global Phase III study results of eribulin mesylate

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference